|Asthma atlas single map||Asthma atlas double map||Asthma consumer summary|
The asthma domain of the Atlas of Healthcare Variation gives clinicians, patients and providers an overview of asthma admission rates and medicine use by district health board (DHB). In order to increase diagnostic certainty and reduce the contribution from chronic obstructive pulmonary disease (COPD), only data for adults aged less than 50 years are included.
Detailed information on the indicators, data sources, definitions, ages and rationale can be found in the methodology.
Update 2014 data
(Updated June 2016)
Pacific and Māori children are more likely to be admitted than European/Other
- On average, 5.8 per 1000 children (~5,000) are admitted one or more times with a primary diagnosis of asthma each year. Rates varied more than two-fold between DHBs.
- The proportion of Pacific (10.4/1000) and Māori (7.3/1000) children admitted was statistically significantly higher than for European/Other children (4.5/1000).
- Younger children (aged 0 to 4 years) had the highest rate of admission.
- Boys were more likely to be admitted than girls.
Pacific and Māori adults (aged less than 50 years) are more likely to be admitted with asthma than European/Other
- On average 1.0 per 1000 adults are admitted one or more times in a year with a primary diagnosis of asthma. This varied three-fold between DHBs.
- Pacific people and Māori had twice the admission rate of European/Other.
- Females had twice as many admissions compared to males.
|Admissions with a primary diagnosis of asthma by age and ethnicity (2014), rate per 1000|
|0–4 years||5–9 years||10–14 years||15–24 years||25–49 years|
At all ages, on average 14 percent of those admitted with asthma had a second admission within 90 days
- A high rate of admissions within 90 days of discharge, suggests there may be room for improvement in discharge planning or continuity of care.
- Māori aged 10–14 and Pacific people aged 25–49 had higher rates.
|Those with at least two admissions with asthma within 90 days of each other, by age and ethnicity (2014), percent|
|1–4 years||5–9 years||10–14 years||15–24 years||25–49 years||Total|
18 percent people admitted had at least two admissions between 91–365 days of each other
- High readmission rates within three months to one year post-discharge, highlight the potential for community follow-up of people admitted with asthma.
- As with readmissions within three months, Māori and Pacific people aged 10–24 had higher admission rates. There was limited variation between DHBs.
|Those with at least two admissions with asthma between 91-365 days of each other, by age and ethnicity (2014), percent|
36 percent of people admitted with asthma were not regularly dispensed an inhaled corticosteroid (ICS) in the year after admission
- It is recommended that all people admitted with asthma should regularly receive ICS following admission. High rates not on regular ICS in the year post-discharge raise questions as to why this might be. Is there potential to improve ongoing chronic condition management?
- On average, 36 percent of people aged 5–49 years admitted with a primary diagnosis of asthma, did not receive ICS in two or more quarters in the year after admission. This did not vary widely between DHBs.
- Children aged 0–4 years were not included in indicators looking at medication use as they are a unique group. Not all will respond to ICS therapy and of those who do, only some will have asthma at school age or as an adult.
82 percent of those aged 0–49 years did not receive a funded influenza vaccine in the year after admission
- Those who have a hospital admission for asthma are recommended to receive regular ICS therapy to manage their asthma. Influenza vaccine is also considered part of their preventive care. Pharmac funds the influenza vaccine for this group.
- Overall, the percent of those hospitalised with asthma receiving the flu vaccine was low and ranged from 13–26 percent of those admitted with a primary diagnosis of asthma.
- Māori (87 percent) and Pacific people (86 percent) groups were significantly less likely to receive influenza vaccine compared to European/Other group (80 percent).
- Influenza vaccination was significantly lower in those aged 0–4 years (only 12 percent received it), compared to all other ages.
- Flu vaccinations that are administered in hospital, self-funded or funded by another third party won’t be included here. It is expected that self-funded/alternately funded is likely to biased towards working age groups. It is considered that these exclusions are unlikely to explain the entire treatment gap.
These indicators look at those in the general population who had a community dispensing of a reliever (SABA) inhaler and a preventer (inhaled corticosteroid or other) in a year
Children aged 0–4 years were not included in indicators looking at medication use as they are a unique group. Not all will respond to ICS therapy and of those who do, only some will have asthma at school age or as an adult.
The data presented do not allow for analysis of patients’ condition or their need for treatment. This means it is not possible to assess the appropriateness or otherwise of prescribing. However wide variation at the population level, both between DHBs and by age or ethnic group is a starting point for asking whether the variation looks appropriate or if there are people who may benefit from preventer medication.
19 percent of those regularly dispensed SABA were not dispensed any preventer medication
- It is recommended that good control of asthma shows little use of SABA (reliever) medication. Preventer (ICS or other preventer) should be introduced if people are using their reliever two or more times in a week.
- This indicator shows that 19 percent of those dispensed SABA in two or more quarters in a year, were not dispensed any preventer medication in the year.
- Pacific people (21 percent) were significantly less likely to receive preventer than Māori (18 percent) or European/Other (19 percent).
- Those aged 5–9 years also received significantly less preventer than all other age groups.
- There was limited variation between DHBs.
31 percent people regularly dispensed SABA were not regularly dispensed a preventer
- Good control of asthma should show little use of relievers and regular use of preventers.
- This indicator shows that 31 percent of people regularly dispensed SABA in two or more quarters in a year, were not also regularly dispensed a preventer (in two or more quarters in a year).
- There was no significant variation by ethnicity. Preventer use was significantly lower in those aged 5–9 years at 37 percent compared with 29 percent of those aged 24–49 years. This did not vary widely by DHB.
What questions might these data prompt?
- Why do some DHBs have consistently lower or higher rates than the national mean?
- Does this variation reflect differences in patient population or are there other factors?
- How do DHBs with similar populations compare?
The rates of medication use including ICS and influenza vaccine in the year after discharge raise questions as to why this might be:
- What proportion of those not recieving an ICS were readmitted?
- What do patients understand with regards to the use of ICS and reliever medication?
- How much of the gap can be explained by medication dispensing that is not captured, for example, prior to admission, free samples or oral steroids?
Asthma is a chronic condition affecting the airways. Internationally, New Zealand has a high prevalence of asthma, with one in seven children (15 percent) aged 2–14 years (120,000 children) and one in nine adults (11 percent, 401,000 adults) reporting taking current asthma medication. OECD statistics indicate New Zealand has the fourth highest hospital admission rates for asthma of OECD countries.
The Respiratory Impact report (2015) presents data on asthma mortality rates. In 2011, 69 people died from asthma. Between 2006–11 asthma mortality was highest in people aged 65 and over and higher in women than in men. Asthma mortality rates were highest for Māori and Pacific peoples, with rates 4.8 and 5.8 times higher than rates for those of other ethnicity. There were socio-economic differences in asthma mortality, with higher deprivation (quintile 9 and 10) rates being 3.1 times higher than the least deprived (quintile 1 and 2).
Data sources and method
The Atlas draws on existing national data collections held by the Ministry of Health, including the National Minimum Dataset (NMDS) and the Pharmaceutical Collection.
The indicators looking at admissions combines data for emergency department attendances meeting the three-hour rule and for hospital admissions. This is because different DHBs handle emergency department attendances differently. For more information see the methodology.
Due to the uncertainty of diagnosing asthma in children under five years, ‘wheeze’ as an alternate diagnosis was included in the indicator reporting hospital admissions in children. Further analysis in the methodology demonstrates higher use of this code in the 0–4 year age group and significant variation between DHBs in the use of ‘wheeze’ as a diagnosis.
- The New Zealand Health Survey is available on the Ministry of Health’s website: www.health.govt.nz/nz-health-statistics/national-collections-and-surveys/surveys/current-recent-surveys/new-zealand-health-survey
- The Australian Asthma Handbook (2014): www.nationalasthma.org.au/handbook
- The British Thoracic Society and SIGN Asthma Guideline (2012): https://www.brit-thoracic.org.uk/guidelines-and-quality-standards/asthma-guideline/
- Beasley R, Hancox RJ, Harwood M et al. Asthma and Respiratory Foundation NZ adult asthma guidelines: a quick reference guide. 2016. NZ Med J 129 (1445). URL: http://www.nzasthmaguidelines.co.nz/uploads/8/3/0/1/83014052/adult_asthma_guidelines.pdf.
- New Zealand Health Survey: Annual update of key findings 2014–15, URL: http://health.govt.nz/publication/annual-update-key-results-2014-15-new-zealand-health-survey.
- Telfar Barnard L, Baker M, Pierse N, Zhang J. 2015. The impact of respiratory disease in New Zealand: 2014 update. Wellington: The Asthma and Respiratory Foundation NZ.